Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's 5th Largest Position

Altium Capital Management LLC increased its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 8.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,850,000 shares of the company's stock after acquiring an additional 150,000 shares during the quarter. Zevra Therapeutics comprises about 4.4% of Altium Capital Management LLC's investment portfolio, making the stock its 5th biggest holding. Altium Capital Management LLC owned about 3.47% of Zevra Therapeutics worth $15,429,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Barclays PLC increased its stake in Zevra Therapeutics by 402.9% during the 4th quarter. Barclays PLC now owns 289,688 shares of the company's stock valued at $2,416,000 after purchasing an additional 232,089 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $224,000. Invesco Ltd. raised its holdings in Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after acquiring an additional 3,007 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Zevra Therapeutics by 65.4% during the fourth quarter. Wells Fargo & Company MN now owns 29,701 shares of the company's stock valued at $248,000 after purchasing an additional 11,744 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock valued at $9,912,000 after acquiring an additional 144,256 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Insider Transactions at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares of the company's stock, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares of the company's stock, valued at $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock valued at $674,176 over the last 90 days. Company insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ZVRA shares. Canaccord Genuity Group boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Guggenheim increased their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Zevra Therapeutics has a consensus rating of "Buy" and a consensus price target of $22.29.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA traded up $0.10 on Friday, reaching $7.15. 406,058 shares of the stock were exchanged, compared to its average volume of 606,022. The firm has a market capitalization of $386.93 million, a PE ratio of -3.63 and a beta of 1.94. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The company's 50-day simple moving average is $7.60 and its two-hundred day simple moving average is $8.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million. Analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.